Kangstem Biotech Co., Ltd. (KOSDAQ:217730)
South Korea · Delayed Price · Currency is KRW 1,891.00
-75.00 (-3.81%)
At close: Oct 22, 2026
Kangstem Biotech Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 3,035 | 3,572 | 7,746 | 12,704 | 16,301 | 12,405 |
Revenue Growth | -76.24% | -53.88% | -39.03% | -22.06% | 31.41% | 35.75% |
Gross Profit Gross Profit Growth | 413.99 | 845.01 | 4,325 | 1,643 | 4,873 | 2,689 |
Operating Income Operating Income Growth | -19,120 | -17,668 | -14,842 | -22,777 | -20,558 | -22,736 |
Net Income Net Income Growth | -11,572 | -10,482 | -7,669 | -21,949 | -20,236 | -21,348 |
Earnings Per Share EPS Growth | -130.90 | -151.00 | -136.95 | -540.61 | -533.40 | -766.61 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cosmetics Cosmetics Growth | 881.27 | 1,204 | 3,274 | 4,117 | 4,009 | 3,182 |
Stem Cell Stem Cell Growth | 2,153 | 2,369 | 4,386 | 1,444 | 1,343 | 691.52 |
Biopharma Biopharma Growth | - | - | 86.03 | 351.38 | 562.54 | - |
Total Total Growth | 3,035 | 3,572 | 7,746 | 12,704 | 16,301 | 12,405 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 27,412 | 38,569 | 18,267 | 37,360 | 36,678 | 56,585 |
Total Debt Total Debt Growth | 9,187 | 9,400 | 8,456 | 13,609 | 13,369 | 14,044 |
Net Cash (Debt) Net Cash Growth | 18,225 | 29,169 | 9,811 | 23,751 | 23,309 | 42,542 |
Net Cash Growth | 0.08% | 197.32% | -58.69% | 1.90% | -45.21% | 115.13% |
Net Cash Per Share Net Cash Per Share Growth | 205.97 | 419.79 | 175.19 | 584.98 | 614.40 | 1527.64 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -16,646 | -11,676 | -18,987 | -16,498 | -18,864 | -16,994 |
Capital Expenditures CapEx Growth | -364.51 | -660.84 | -593.45 | -1,392 | -712.42 | -4,631 |
Free Cash Flow Free Cash Flow Growth | -17,010 | -12,337 | -19,581 | -17,890 | -19,576 | -21,624 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 13.64% | 23.65% | 55.84% | 12.93% | 29.89% | 21.68% |
Operating Margin | -630.05% | -494.56% | -191.62% | -179.29% | -126.12% | -183.28% |
Pretax Margin | -380.85% | -293.00% | -91.44% | -182.13% | -124.02% | -175.83% |
Profit Margin | -381.33% | -293.41% | -99.01% | -172.77% | -124.14% | -172.10% |
FCF Margin | -560.53% | -345.33% | -252.79% | -140.82% | -120.10% | -174.32% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 58.61 | 61.08 | 14.62 | 10.55 | 6.74 | 10.00 |